TBC1D9

Chr 4

TBC1 domain family member 9

Also known as: GRAMD9, MDR1

Predicted to enable GTPase activator activity. Predicted to be involved in system process. [provided by Alliance of Genome Resources, Jun 2026]

OMIMResearchGenerating clinical summary…

Clinical highlights

Interpreting a novel variant
This gene is strongly intolerant of loss-of-function variation in the population, so LoF variants warrant close attention. No curated mechanism annotation is available — see the mechanism card for the computational prediction and its caveats.Based on population constraint only.
0
Active trials
4
Pubs (1 yr)
P/LP submissions
P/LP missense
0.49
LOEUF
Multiple*
Mechanism· predicted

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Missense constrained — critical functional residues
LoF Constraint?
0.49LOEUF
pLI 0.000
Z-score 4.69
OE 0.33 (0.230.49)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?
3.16Z-score
OE missense 0.67 (0.620.72)
483 obs / 721.9 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios?
LoF OE?0.33 (0.230.49)
00.351.4
Missense OE?0.67 (0.620.72)
00.61.4
Synonymous OE?0.93
01.21.6
LoF obs/exp: 19 / 57.3Missense obs/exp: 483 / 721.9Syn Z: 0.98

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

TBC1D9 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →